3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
63
Neoplasms
7
Neoplasms, Plasma Cell
6
Recurrence
5
Hematologic Neoplasms
4
Renal Insufficiency
3
Paraproteinemias
3
Lymphoma
3
Immunoglobulin Light-chain Amyloidosis
3
Hematologic Diseases
3
Smoldering Multiple Myeloma
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms by Histologic Type
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myeloid, Acute
2
Leukemia
2
Blood Protein Disorders
2
Purpura
1
Prostatic Neoplasms
1
Neoplasm, Residual
1
Nausea
1
Natural Killer/T-cell Lymphoma
1
Monoclonal Gammopathy of Undetermined Significance
1
Macroglossia
1
Lymphoproliferative Disorders
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphadenopathy
1
Leukemia, Plasma Cell
1
Immunoproliferative Disorders
1
Interventions
Peripheral Blood Stem Cell Transplantation
4
Cyclophosphamide
4
Epoetin Alfa
3
Darbepoetin alfa
3
Curcumin
3
liposomal amphotericin B
2
fludarabine phosphate
2
Morphine
2
Methylprednisolone
2
Interferon-alpha
2
Filgrastim
2
Cyclosporine
2
Caspofungin
2
Carboplatin
2
Bortezomib
2
Antilymphocyte Serum
2
tanespimycin
1
siltuximab
1
sargramostim
1
pyroxamide
1
piperine
1
isatuximab
1
ibrutinib
1
ferrous sulfate
1
ferric gluconate
1
alethine
1
aldesleukin
1
Whole-Body Irradiation
1
Topotecan
1
Therapeutics
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Monoclonal Gammopathy of Undetermined Significance
×
isatuximab
×
Clear all
NCT05114109
2021-11-09
ICE
Assistance Publique - Hôpitaux de Paris
Phase 2
Unknown
21 enrolled